BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Durán-Prado M, Gahete MD, Martínez-Fuentes AJ, Luque RM, Quintero A, Webb SM, Benito-López P, Leal A, Schulz S, Gracia-Navarro F, Malagón MM, Castaño JP. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab 2009;94:2634-43. [PMID: 19401364 DOI: 10.1210/jc.2008-2564] [Cited by in Crossref: 106] [Cited by in F6Publishing: 107] [Article Influence: 8.2] [Reference Citation Analysis]
Number Citing Articles
1 Domingo B, Gasset M, Durán-Prado M, Castaño JP, Serrano A, Fischer T, Llopis J. Discrimination between alternate membrane protein topologies in living cells using GFP/YFP tagging and pH exchange. Cell Mol Life Sci 2010;67:3345-54. [PMID: 20454916 DOI: 10.1007/s00018-010-0386-7] [Reference Citation Analysis]
2 Peverelli E, Treppiedi D, Giardino E, Vitali E, Lania AG, Mantovani G. Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement. Front Endocrinol (Lausanne) 2015;6:187. [PMID: 26733942 DOI: 10.3389/fendo.2015.00187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
3 Ku CR, Melnikov V, Zhang Z, Lee EJ. Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality? Endocrinol Metab (Seoul) 2020;35:206-16. [PMID: 32615705 DOI: 10.3803/EnM.2020.35.2.206] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Schulz S, Lehmann A, Kliewer A, Nagel F. Fine-tuning somatostatin receptor signalling by agonist-selective phosphorylation and dephosphorylation: IUPHAR Review 5. Br J Pharmacol 2014;171:1591-9. [PMID: 24328848 DOI: 10.1111/bph.12551] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lequoy M, Desbois-mouthon C, Wendum D, Gupta V, Blachon J, Scatton O, Dumont S, Bonnemaire M, Schmidlin F, Rosmorduc O, Fartoux L. Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis. Histopathology 2017;70:492-8. [DOI: 10.1111/his.13034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
6 Barbieri F, Albertelli M, Grillo F, Mohamed A, Saveanu A, Barlier A, Ferone D, Florio T. Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies. Drug Discovery Today 2014;19:458-68. [DOI: 10.1016/j.drudis.2013.10.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
7 Vandeva S, Elenkova A, Natchev E, Zacharieva S. Epidemiological variations of aggressive growth hormone-secreting adenomas. International Journal of Endocrine Oncology 2016;3:245-57. [DOI: 10.2217/ije-2015-0011] [Reference Citation Analysis]
8 Vázquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cortés E, Dios E, Moreno-Moreno P, Madrazo-Atutxa A, Remón P, Solivera J, Wildemberg LE, Kasuki L, López-Fernández JM, Gadelha MR, Gálvez-Moreno MA, Soto-Moreno A, Gahete MD, Castaño JP, Luque RM. Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features. Cancers (Basel) 2019;11:E1439. [PMID: 31561558 DOI: 10.3390/cancers11101439] [Reference Citation Analysis]
9 Ibáñez-Costa A, Korbonits M. AIP and the somatostatin system in pituitary tumours. J Endocrinol 2017;235:R101-16. [PMID: 28835453 DOI: 10.1530/JOE-17-0254] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
10 Fuentes-Fayos AC, G-García ME, Pérez-Gómez JM, Peel A, Blanco-Acevedo C, Solivera J, Ibáñez-Costa A, Gahete MD, Castaño JP, Luque RM. Somatostatin Receptor Splicing Variant sst5TMD4 Overexpression in Glioblastoma Is Associated with Poor Survival, Increased Aggressiveness Features, and Somatostatin Analogs Resistance. Int J Mol Sci 2022;23:1143. [PMID: 35163067 DOI: 10.3390/ijms23031143] [Reference Citation Analysis]
11 Ibáñez-Costa A, López-Sánchez LM, Gahete MD, Rivero-Cortés E, Vázquez-Borrego MC, Gálvez MA, de la Riva A, Venegas-Moreno E, Jiménez-Reina L, Moreno-Carazo A, Tinahones FJ, Maraver-Selfa S, Japón MA, García-Arnés JA, Soto-Moreno A, Webb SM, Kineman RD, Culler MD, Castaño JP, Luque RM. BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas. Sci Rep 2017;7:42002. [PMID: 28181484 DOI: 10.1038/srep42002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
12 Fuentes-Fayos AC, García-Martínez A, Herrera-Martínez AD, Jiménez-Vacas JM, Vázquez-Borrego MC, Castaño JP, Picó A, Gahete MD, Luque RM. Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors. Minerva Endocrinol 2019;44:109-28. [PMID: 30650942 DOI: 10.23736/S0391-1977.19.02970-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 5.7] [Reference Citation Analysis]
13 Luque RM, Ibáñez-Costa A, Neto LV, Taboada GF, Hormaechea-Agulla D, Kasuki L, Venegas-Moreno E, Moreno-Carazo A, Gálvez MÁ, Soto-Moreno A, Kineman RD, Culler MD, Gahete MD, Gadelha MR, Castaño JP. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas. Cancer Lett 2015;359:299-306. [PMID: 25637790 DOI: 10.1016/j.canlet.2015.01.037] [Cited by in Crossref: 57] [Cited by in F6Publishing: 65] [Article Influence: 8.1] [Reference Citation Analysis]
14 Khor EC, Yulyaningsih E, Driessler F, Kovaĉić N, Wee NKY, Kulkarni RN, Lee NJ, Enriquez RF, Xu J, Zhang L, Herzog H, Baldock PA. The y6 receptor suppresses bone resorption and stimulates bone formation in mice via a suprachiasmatic nucleus relay. Bone 2016;84:139-47. [PMID: 26721736 DOI: 10.1016/j.bone.2015.12.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
15 Ben-Shlomo A, Liu NA, Melmed S. Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas. Pituitary 2017;20:93-9. [PMID: 27900635 DOI: 10.1007/s11102-016-0778-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
16 Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler M, Melmed S, Schulz S. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol Rev 2018;70:763-835. [PMID: 30232095 DOI: 10.1124/pr.117.015388] [Cited by in Crossref: 93] [Cited by in F6Publishing: 79] [Article Influence: 31.0] [Reference Citation Analysis]
17 Luque RM, Ibáñez-Costa A, Neto LV, Taboada GF, Hormaechea-Agulla D, Kasuki L, Venegas-Moreno E, Moreno-Carazo A, Gálvez MÁ, Soto-Moreno A, Kineman RD, Culler MD, Gahete MD, Gadelha MR, Castaño JP. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas. Cancer Lett 2015;359:299-306. [PMID: 25637790 DOI: 10.1016/j.canlet.2015.01.037] [Reference Citation Analysis]
18 Trouillas J, Vasiljevic A, Lapoirie M, Chinezu L, Jouanneau E, Raverot G. Pathological markers of somatotroph pituitary neuroendocrine tumors predicting the response to medical treatment. Minerva Endocrinol 2019;44. [DOI: 10.23736/s0391-1977.18.02933-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 3.7] [Reference Citation Analysis]
19 Moreno-Moreno P, Ibáñez-Costa A, Venegas-Moreno E, Fuentes-Fayos AC, Alhambra-Expósito MR, Fajardo-Montañana C, García-Martínez A, Dios E, Vázquez-Borrego MC, Remón-Ruiz P, Cámara R, Lamas C, Carlos Padillo-Cuenca J, Solivera J, Cano DA, Gahete MD, Herrera-Martínez AD, Picó A, Soto-Moreno A, Gálvez-Moreno MÁ, Castaño JP, Luque RM. Integrative Clinical, Radiological, and Molecular Analysis for Predicting Remission and Recurrence of Cushing Disease. J Clin Endocrinol Metab 2022;107:e2938-51. [PMID: 35312002 DOI: 10.1210/clinem/dgac172] [Reference Citation Analysis]
20 Li SC, Martijn C, Cui T, Essaghir A, Luque RM, Demoulin JB, Castaño JP, Öberg K, Giandomenico V. The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells. PLoS One 2012;7:e48411. [PMID: 23119007 DOI: 10.1371/journal.pone.0048411] [Reference Citation Analysis]
21 Pedraza-Arévalo S, Hormaechea-Agulla D, Gómez-Gómez E, Requena MJ, Selth LA, Gahete MD, Castaño JP, Luque RM. Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer. Prostate 2017;77:1499-511. [PMID: 28905400 DOI: 10.1002/pros.23426] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
22 Wise H. The roles played by highly truncated splice variants of G protein-coupled receptors. J Mol Signal 2012;7:13. [PMID: 22938630 DOI: 10.1186/1750-2187-7-13] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
23 Molè D, Gentilin E, Ibañez-Costa A, Gagliano T, Gahete MD, Tagliati F, Rossi R, Pelizzo MR, Pansini G, Luque RM, Castaño JP, degli Uberti E, Zatelli MC. The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells. Endocrine 2015;50:442-52. [PMID: 25854304 DOI: 10.1007/s12020-015-0594-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
24 Córdoba-Chacón J, Gahete MD, Duran-Prado M, Pozo-Salas AI, Malagón MM, Gracia-Navarro F, Kineman RD, Luque RM, Castaño JP. Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents. Cell Mol Life Sci 2010;67:1147-63. [PMID: 20063038 DOI: 10.1007/s00018-009-0240-y] [Reference Citation Analysis]
25 Kasuki L, Colli LM, Elias PCL, Castro MD, Gadelha MR. Resistance to octreotide LAR in acromegalic patients with high SSTR2 expression: analysis of AIP expression. Arq Bras Endocrinol Metab 2012;56:501-6. [DOI: 10.1590/s0004-27302012000800007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
26 Beckers A, Aaltonen LA, Daly AF, Karhu A. Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 2013;34:239-77. [PMID: 23371967 DOI: 10.1210/er.2012-1013] [Cited by in Crossref: 209] [Cited by in F6Publishing: 153] [Article Influence: 23.2] [Reference Citation Analysis]
27 Córdoba-Chacón J, Gahete MD, Castaño JP, Kineman RD, Luque RM. Somatostatin and its receptors contribute in a tissue-specific manner to the sex-dependent metabolic (fed/fasting) control of growth hormone axis in mice. Am J Physiol Endocrinol Metab 2011;300:E46-54. [PMID: 20943754 DOI: 10.1152/ajpendo.00514.2010] [Reference Citation Analysis]
28 Hormaechea-Agulla D, Jiménez-Vacas JM, Gómez-Gómez E, L-López F, Carrasco-Valiente J, Valero-Rosa J, Moreno MM, Sánchez-Sánchez R, Ortega-Salas R, Gracia-Navarro F, Culler MD, Ibáñez-Costa A, Gahete MD, Requena MJ, Castaño JP, Luque RM. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer. FASEB J 2017;31:4682-96. [PMID: 28705809 DOI: 10.1096/fj.201601264RRR] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 5.6] [Reference Citation Analysis]
29 Córdoba-Chacón J, Gahete MD, Castaño JP, Kineman RD, Luque RM. Somatostatin and its receptors contribute in a tissue-specific manner to the sex-dependent metabolic (fed/fasting) control of growth hormone axis in mice. Am J Physiol Endocrinol Metab 2011;300:E46-54. [PMID: 20943754 DOI: 10.1152/ajpendo.00514.2010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
30 Herrera-Martínez AD, Gahete MD, Sánchez-Sánchez R, Salas RO, Serrano-Blanch R, Salvatierra Á, Hofland LJ, Luque RM, Gálvez-Moreno MA, Castaño JP. The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features. Lung Cancer 2017;109:128-36. [PMID: 28577942 DOI: 10.1016/j.lungcan.2017.05.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
31 Fuentes-Fayos AC, Vázquez-Borrego MC, Jiménez-Vacas JM, Bejarano L, Pedraza-Arévalo S, L-López F, Blanco-Acevedo C, Sánchez-Sánchez R, Reyes O, Ventura S, Solivera J, Breunig JJ, Blasco MA, Gahete MD, Castaño JP, Luque RM. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3. Brain 2020;143:3273-93. [PMID: 33141183 DOI: 10.1093/brain/awaa273] [Reference Citation Analysis]
32 Cakir M, Dworakowska D, Grossman A. Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways. J Cell Mol Med 2010;14:2570-84. [PMID: 20629989 DOI: 10.1111/j.1582-4934.2010.01125.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
33 Barbieri F, Bajetto A, Pattarozzi A, Gatti M, Würth R, Thellung S, Corsaro A, Villa V, Nizzari M, Florio T. Peptide receptor targeting in cancer: the somatostatin paradigm. Int J Pept 2013;2013:926295. [PMID: 23476673 DOI: 10.1155/2013/926295] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 6.3] [Reference Citation Analysis]
34 Schober DA, Croy CH, Ruble CL, Tao R, Felder CC. Identification, expression and functional characterization of M4L, a muscarinic acetylcholine M4 receptor splice variant. PLoS One 2017;12:e0188330. [PMID: 29211764 DOI: 10.1371/journal.pone.0188330] [Reference Citation Analysis]
35 Herrera-Martínez AD, Gahete MD, Pedraza-Arevalo S, Sánchez-Sánchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Gálvez-Moreno MA, Castaño JP. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Endocrine 2018;59:426-37. [PMID: 29196939 DOI: 10.1007/s12020-017-1482-3] [Reference Citation Analysis]
36 Vázquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cortés E, Dios E, Moreno-Moreno P, Madrazo-Atutxa A, Remón P, Solivera J, Wildemberg LE, Kasuki L, López-Fernández JM, Gadelha MR, Gálvez-Moreno MA, Soto-Moreno A, Gahete MD, Castaño JP, Luque RM. Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features. Cancers (Basel) 2019;11:E1439. [PMID: 31561558 DOI: 10.3390/cancers11101439] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
37 Peverelli E, Treppiedi D, Mangili F, Catalano R, Spada A, Mantovani G. Drug resistance in pituitary tumours: from cell membrane to intracellular signalling. Nat Rev Endocrinol 2021;17:560-71. [PMID: 34194011 DOI: 10.1038/s41574-021-00514-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
38 Ibáñez-Costa A, Rivero-Cortés E, Vázquez-Borrego MC, Gahete MD, Jiménez-Reina L, Venegas-Moreno E, de la Riva A, Arráez MÁ, González-Molero I, Schmid HA, Maraver-Selfa S, Gavilán-Villarejo I, García-Arnés JA, Japón MA, Soto-Moreno A, Gálvez MA, Luque RM, Castaño JP. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro. J Endocrinol 2016;231:135-45. [PMID: 27587848 DOI: 10.1530/JOE-16-0332] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 8.3] [Reference Citation Analysis]
39 Vázquez-Borrego MC, Fuentes-Fayos AC, Herrera-Martínez AD, Venegas-Moreno E, L-López F, Fanciulli A, Moreno-Moreno P, Alhambra-Expósito MR, Barrera-Martín A, Dios E, Blanco-Acevedo C, Solivera J, Granata R, Kineman RD, Gahete MD, Soto-Moreno A, Gálvez-Moreno MA, Castaño JP, Luque RM. Statins Directly Regulate Pituitary Cell Function and Exert Antitumor Effects in Pituitary Tumors. Neuroendocrinology 2020;110:1028-41. [PMID: 31940630 DOI: 10.1159/000505923] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
40 Marina D, Burman P, Klose M, Casar-Borota O, Luque RM, Castaño JP, Feldt-Rasmussen U. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache. Growth Horm IGF Res 2015;25:262-7. [PMID: 26188991 DOI: 10.1016/j.ghir.2015.07.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
41 Gahete MD, Durán-Prado M, Delgado-Niebla E, Garrido JJ, Rhodes SJ, García-Navarro S, Gracia-Navarro F, Malagón MM, Luque RM, Castaño JP. Porcine sst1 can physically interact with other somatostatin receptors, and its expression is regulated by metabolic/inflammatory sensors. Am J Physiol Endocrinol Metab 2014;306:E483-93. [PMID: 24368669 DOI: 10.1152/ajpendo.00587.2013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Iguchi Y, Ishii J, Nakayama H, Ishikura A, Izawa K, Tanaka T, Ogino C, Kondo A. Control of signalling properties of human somatostatin receptor subtype-5 by additional signal sequences on its amino-terminus in yeast. Journal of Biochemistry 2010;147:875-84. [DOI: 10.1093/jb/mvq023] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
43 Gahete MD, Cordoba-Chacón J, Duran-Prado M, Malagón MM, Martinez-Fuentes AJ, Gracia-Navarro F, Luque RM, Castaño JP. Somatostatin and its receptors from fish to mammals. Ann N Y Acad Sci 2010;1200:43-52. [PMID: 20633132 DOI: 10.1111/j.1749-6632.2010.05511.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 4.3] [Reference Citation Analysis]
44 Otsuka F, Tsukamoto N, Miyoshi T, Iwasaki Y, Makino H. BMP action in the pituitary: its possible role in modulating somatostatin sensitivity in pituitary tumor cells. Mol Cell Endocrinol 2012;349:105-10. [PMID: 22056414 DOI: 10.1016/j.mce.2011.10.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
45 Fuentes-Fayos AC, Pérez-Gómez JM, G-García ME, Jiménez-Vacas JM, Blanco-Acevedo C, Sánchez-Sánchez R, Solivera J, Breunig JJ, Gahete MD, Castaño JP, Luque RM. SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances. J Exp Clin Cancer Res 2022;41:39. [PMID: 35086552 DOI: 10.1186/s13046-022-02241-4] [Reference Citation Analysis]
46 Del Rio-Moreno M, Alors-Perez E, Borges de Souza P, Prados-Gonzalez ME, CastaÑo JP, Luque RM, Gahete MD. Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types. Transl Res 2019;211:147-60. [PMID: 30904441 DOI: 10.1016/j.trsl.2019.02.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
47 Ibáñez-Costa A, López-Sánchez LM, Gahete MD, Rivero-Cortés E, Vázquez-Borrego MC, Gálvez MA, de la Riva A, Venegas-Moreno E, Jiménez-Reina L, Moreno-Carazo A, Tinahones FJ, Maraver-Selfa S, Japón MA, García-Arnés JA, Soto-Moreno A, Webb SM, Kineman RD, Culler MD, Castaño JP, Luque RM. BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas. Sci Rep 2017;7:42002. [PMID: 28181484 DOI: 10.1038/srep42002] [Reference Citation Analysis]
48 Durán-Prado M, Gahete MD, Hergueta-Redondo M, Martínez-Fuentes AJ, Córdoba-Chacón J, Palacios J, Gracia-Navarro F, Moreno-Bueno G, Malagón MM, Luque RM, Castaño JP. The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells. Oncogene 2012;31:2049-61. [PMID: 21927030 DOI: 10.1038/onc.2011.389] [Cited by in Crossref: 55] [Cited by in F6Publishing: 69] [Article Influence: 5.5] [Reference Citation Analysis]
49 Vázquez-Borrego MC, L-López F, Gálvez-Moreno MA, Fuentes-Fayos AC, Venegas-Moreno E, Herrera-Martínez AD, Blanco-Acevedo C, Solivera J, Landsman T, Gahete MD, Soto-Moreno A, Culler MD, Castaño JP, Luque RM. A New Generation Somatostatin-Dopamine Analogue Exerts Potent Antitumoral Actions on Pituitary Neuroendocrine Tumor Cells. Neuroendocrinology 2020;110:70-82. [PMID: 31272096 DOI: 10.1159/000500812] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
50 Stengel A, Rivier J, Taché Y. Modulation of the adaptive response to stress by brain activation of selective somatostatin receptor subtypes. Peptides 2013;42:70-7. [PMID: 23287111 DOI: 10.1016/j.peptides.2012.12.022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
51 Qing R, Tao F, Chatterjee P, Yang G, Han Q, Chung H, Ni J, Suter BP, Kubicek J, Maertens B, Schubert T, Blackburn C, Zhang S. Non-full-length Water-Soluble CXCR4QTY and CCR5QTY Chemokine Receptors: Implication for Overlooked Truncated but Functional Membrane Receptors. iScience 2020;23:101670. [PMID: 33376963 DOI: 10.1016/j.isci.2020.101670] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Wildemberg LE, Kasuki L, Gadelha MR. Precision medicine in the medical management of pituitary tumors. Current Opinion in Endocrine and Metabolic Research 2018;1:57-62. [DOI: 10.1016/j.coemr.2018.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
53 De Ravin E, Phan HAT, Harmsen S, Cho SS, Teng CW, Petersson EJ, White C, Galban EM, Hess R, Lee JYK. Somatostatin Receptor as a Molecular Imaging Target in Human and Canine Cushing Disease. World Neurosurg 2021;149:94-102. [PMID: 33601082 DOI: 10.1016/j.wneu.2021.02.034] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Stengel A, Taché Y. Central somatostatin signaling and regulation of food intake. Ann N Y Acad Sci 2019;1455:98-104. [PMID: 31237362 DOI: 10.1111/nyas.14178] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
55 Li SC, Martijn C, Cui T, Essaghir A, Luque RM, Demoulin JB, Castaño JP, Öberg K, Giandomenico V. The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells. PLoS One 2012;7:e48411. [PMID: 23119007 DOI: 10.1371/journal.pone.0048411] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
56 Córdoba-Chacón J, Gahete MD, Pozo-Salas AI, Martínez-Fuentes AJ, de Lecea L, Gracia-Navarro F, Kineman RD, Castaño JP, Luque RM. Cortistatin is not a somatostatin analogue but stimulates prolactin release and inhibits GH and ACTH in a gender-dependent fashion: potential role of ghrelin. Endocrinology 2011;152:4800-12. [PMID: 21971153 DOI: 10.1210/en.2011-1542] [Reference Citation Analysis]
57 Piekielko-Witkowska A, Kedzierska H, Poplawski P, Wojcicka A, Rybicka B, Maksymowicz M, Grajkowska W, Matyja E, Mandat T, Bonicki W, Nauman P. Alternative splicing of iodothyronine deiodinases in pituitary adenomas. Regulation by oncoprotein SF2/ASF. Biochim Biophys Acta 2013;1832:763-72. [PMID: 23462647 DOI: 10.1016/j.bbadis.2013.02.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
58 Gatto F, Hofland LJ. The role of somatostatin and dopamine D2 receptors in endocrine tumors. Endocr Relat Cancer 2011;18:R233-51. [PMID: 22135243 DOI: 10.1530/ERC-10-0334] [Cited by in Crossref: 57] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
59 Gonzalez B, Vargas G, Ramirez C, Asa S, Cheng S, Sandoval C, Mercado M. Cytoplasmic expression of SSTR2 and 5 by immunohistochemistry and by RT/PCR is not associated with the pharmacological response to octreotide. Endocrinología y Nutrición 2014;61:523-30. [DOI: 10.1016/j.endonu.2014.05.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
60 Puig-Domingo M, Luque RM, Reverter JL, López-Sánchez LM, Gahete MD, Culler MD, Díaz-Soto G, Lomeña F, Squarcia M, Mate JL, Mora M, Fernández-Cruz L, Vidal O, Alastrué A, Balibrea J, Halperin I, Mauricio D, Castaño JP. The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer. PLoS One 2014;9:e85527. [PMID: 24465589 DOI: 10.1371/journal.pone.0085527] [Cited by in Crossref: 22] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
61 Gahete MD, Córdoba-Chacón J, Hergueta-Redondo M, Martínez-Fuentes AJ, Kineman RD, Moreno-Bueno G, Luque RM, Castaño JP. A novel human ghrelin variant (In1-ghrelin) and ghrelin-O-acyltransferase are overexpressed in breast cancer: potential pathophysiological relevance. PLoS One 2011;6:e23302. [PMID: 21829727 DOI: 10.1371/journal.pone.0023302] [Cited by in Crossref: 52] [Cited by in F6Publishing: 63] [Article Influence: 4.7] [Reference Citation Analysis]
62 Ibáñez-Costa A, Luque RM, Castaño JP. Cortistatin: A new link between the growth hormone/prolactin axis, stress, and metabolism. Growth Horm IGF Res 2017;33:23-7. [PMID: 28157571 DOI: 10.1016/j.ghir.2017.01.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
63 Gahete MD, Luque RM, Yubero-Serrano EM, Cruz-Teno C, Ibañez-Costa A, Delgado-Lista J, Gracia-Navarro F, Perez-Jimenez F, Castaño JP, Lopez-Miranda J. Dietary fat alters the expression of cortistatin and ghrelin systems in the PBMCs of elderly subjects: putative implications in the postprandial inflammatory response. Mol Nutr Food Res 2014;58:1897-906. [PMID: 24995559 DOI: 10.1002/mnfr.201400059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
64 Castaño JP, Sundin A, Maecke HR, Villabona C, Vazquez-Albertino R, Navarro E, Oberg K. Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges. Cancer Metastasis Rev 2014;33:353-9. [PMID: 24390486 DOI: 10.1007/s10555-013-9465-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
65 Herrera-Martínez AD, Pedraza-Arevalo S, L-López F, Gahete MD, Gálvez-Moreno MA, Castaño JP, Luque RM. Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution? J Clin Endocrinol Metab 2019;104:57-73. [PMID: 30265346 DOI: 10.1210/jc.2018-01455] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
66 Ibáñez-Costa A, Gahete MD, Rivero-Cortés E, Rincón-Fernández D, Nelson R, Beltrán M, de la Riva A, Japón MA, Venegas-Moreno E, Gálvez MÁ, García-Arnés JA, Soto-Moreno A, Morgan J, Tsomaia N, Culler MD, Dieguez C, Castaño JP, Luque RM. In1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases their aggressive features. Sci Rep 2015;5:8714. [PMID: 25737012 DOI: 10.1038/srep08714] [Cited by in Crossref: 45] [Cited by in F6Publishing: 53] [Article Influence: 6.4] [Reference Citation Analysis]
67 Domingo B, Gasset M, Durán-Prado M, Castaño JP, Serrano A, Fischer T, Llopis J. Discrimination between alternate membrane protein topologies in living cells using GFP/YFP tagging and pH exchange. Cell Mol Life Sci 2010;67:3345-54. [PMID: 20454916 DOI: 10.1007/s00018-010-0386-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
68 Cuevas-ramos D, Fleseriu M. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. Journal of Molecular Endocrinology 2014;52:R223-40. [DOI: 10.1530/jme-14-0011] [Cited by in Crossref: 94] [Cited by in F6Publishing: 51] [Article Influence: 11.8] [Reference Citation Analysis]
69 Córdoba-Chacón J, Gahete MD, Pozo-Salas AI, Martínez-Fuentes AJ, de Lecea L, Gracia-Navarro F, Kineman RD, Castaño JP, Luque RM. Cortistatin is not a somatostatin analogue but stimulates prolactin release and inhibits GH and ACTH in a gender-dependent fashion: potential role of ghrelin. Endocrinology 2011;152:4800-12. [PMID: 21971153 DOI: 10.1210/en.2011-1542] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
70 Sampedro-Núñez M, Luque RM, Ramos-Levi AM, Gahete MD, Serrano-Somavilla A, Villa-Osaba A, Adrados M, Ibáñez-Costa A, Martín-Pérez E, Culler MD, Marazuela M, Castaño JP. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors. Oncotarget 2016;7:6593-608. [PMID: 26673010 DOI: 10.18632/oncotarget.6565] [Reference Citation Analysis]
71 Zatelli MC, Minoia M, Filieri C, Tagliati F, Buratto M, Ambrosio MR, Lapparelli M, Scanarini M, degli Uberti EC. Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas. The Journal of Clinical Endocrinology & Metabolism 2010;95:968-76. [DOI: 10.1210/jc.2009-1641] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 4.7] [Reference Citation Analysis]
72 Córdoba-Chacón J, Gahete MD, Duran-Prado M, Pozo-Salas AI, Malagón MM, Gracia-Navarro F, Kineman RD, Luque RM, Castaño JP. Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents. Cell Mol Life Sci 2010;67:1147-63. [PMID: 20063038 DOI: 10.1007/s00018-009-0240-y] [Cited by in Crossref: 49] [Cited by in F6Publishing: 57] [Article Influence: 4.1] [Reference Citation Analysis]
73 Durán-Prado M, Saveanu A, Luque RM, Gahete MD, Gracia-Navarro F, Jaquet P, Dufour H, Malagón MM, Culler MD, Barlier A, Castaño JP. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. J Clin Endocrinol Metab 2010;95:2497-502. [PMID: 20233783 DOI: 10.1210/jc.2009-2247] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 5.8] [Reference Citation Analysis]
74 Dong H, Wei Y, Xie C, Zhu X, Sun C, Fu Q, Pan L, Wu M, Guo Y, Sun J, Shen H, Ye J. Structural and functional analysis of two novel somatostatin receptors identified from topmouth culter (Erythroculter ilishaeformis). Comp Biochem Physiol C Toxicol Pharmacol 2018;210:18-29. [PMID: 29698686 DOI: 10.1016/j.cbpc.2018.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 Tsukamoto N, Otsuka F, Miyoshi T, Inagaki K, Nakamura E, Suzuki J, Ogura T, Iwasaki Y, Makino H. Activities of bone morphogenetic proteins in prolactin regulation by somatostatin analogs in rat pituitary GH3 cells. Mol Cell Endocrinol 2011;332:163-9. [PMID: 20970474 DOI: 10.1016/j.mce.2010.10.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
76 Moncayo R. Reflections on the theory of "silver bullet" octreotide tracers: implications for ligand-receptor interactions in the age of peptides, heterodimers, receptor mosaics, truncated receptors, and multifractal analysis. EJNMMI Res 2011;1:9. [PMID: 22214590 DOI: 10.1186/2191-219X-1-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
77 Gahete MD, Rincón-Fernández D, Durán-Prado M, Hergueta-Redondo M, Ibáñez-Costa A, Rojo-Sebastián A, Gracia-Navarro F, Culler MD, Casanovas O, Moreno-Bueno G, Luque RM, Castaño JP. The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients. Oncotarget 2016;7:60110-22. [PMID: 27507050 DOI: 10.18632/oncotarget.11076] [Reference Citation Analysis]
78 Reubi JC, Schonbrunn A. Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol Sci 2013;34:676-88. [PMID: 24183675 DOI: 10.1016/j.tips.2013.10.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 6.8] [Reference Citation Analysis]
79 Fuentes-Fayos AC, G-García ME, Pérez-Gómez JM, Peel A, Blanco-Acevedo C, Solivera J, Ibáñez-Costa A, Gahete MD, Castaño JP, Luque RM. Somatostatin Receptor Splicing Variant sst5TMD4 Overexpression in Glioblastoma Is Associated with Poor Survival, Increased Aggressiveness Features, and Somatostatin Analogs Resistance. Int J Mol Sci 2022;23:1143. [PMID: 35163067 DOI: 10.3390/ijms23031143] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Casar-borota O, Heck A, Schulz S, Nesland JM, Ramm-pettersen J, Lekva T, Alafuzoff I, Bollerslev J. Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in Somatotroph Adenomas Assessed by Monoclonal Antibodies Was Reduced by Octreotide and Correlated With the Acute and Long-Term Effects of Octreotide. The Journal of Clinical Endocrinology & Metabolism 2013;98:E1730-9. [DOI: 10.1210/jc.2013-2145] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 8.1] [Reference Citation Analysis]
81 Stengel A, Taché YF. Activation of Brain Somatostatin Signaling Suppresses CRF Receptor-Mediated Stress Response. Front Neurosci 2017;11:231. [PMID: 28487631 DOI: 10.3389/fnins.2017.00231] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
82 Puig-Domingo M, Bernabéu I, Picó A, Biagetti B, Gil J, Alvarez-Escolá C, Jordà M, Marques-Pamies M, Soldevila B, Gálvez MA, Cámara R, Aller J, Lamas C, Marazuela M. Pasireotide in the Personalized Treatment of Acromegaly. Front Endocrinol (Lausanne) 2021;12:648411. [PMID: 33796079 DOI: 10.3389/fendo.2021.648411] [Reference Citation Analysis]
83 Sampedro-Núñez M, Luque RM, Ramos-Levi AM, Gahete MD, Serrano-Somavilla A, Villa-Osaba A, Adrados M, Ibáñez-Costa A, Martín-Pérez E, Culler MD, Marazuela M, Castaño JP. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors. Oncotarget 2016;7:6593-608. [PMID: 26673010 DOI: 10.18632/oncotarget.6565] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
84 Córdoba-Chacón J, Gahete MD, Durán-Prado M, Luque RM, Castaño JP. Truncated somatostatin receptors as new players in somatostatin-cortistatin pathophysiology. Ann N Y Acad Sci 2011;1220:6-15. [PMID: 21388399 DOI: 10.1111/j.1749-6632.2011.05985.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
85 Stengel A, Karasawa H, Taché Y. The role of brain somatostatin receptor 2 in the regulation of feeding and drinking behavior. Horm Behav 2015;73:15-22. [PMID: 26026616 DOI: 10.1016/j.yhbeh.2015.05.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
86 Sanchez C, Escrieut C, Clerc P, Gigoux V, Waser B, Reubi JC, Fourmy D. Characterization of a novel five-transmembrane domain cholecystokinin-2 receptor splice variant identified in human tumors. Mol Cell Endocrinol. 2012;349:170-179. [PMID: 22040601 DOI: 10.1016/j.mce.2011.10.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
87 Gahete MD, Rincón-Fernández D, Durán-Prado M, Hergueta-Redondo M, Ibáñez-Costa A, Rojo-Sebastián A, Gracia-Navarro F, Culler MD, Casanovas O, Moreno-Bueno G, Luque RM, Castaño JP. The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients. Oncotarget 2016;7:60110-22. [PMID: 27507050 DOI: 10.18632/oncotarget.11076] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
88 Annunziata M, Luque RM, Durán-Prado M, Baragli A, Grande C, Volante M, Gahete MD, Deltetto F, Camanni M, Ghigo E, Castaño JP, Granata R. Somatostatin and somatostatin analogues reduce PDGF-induced endometrial cell proliferation and motility. Hum Reprod 2012;27:2117-29. [PMID: 22588000 DOI: 10.1093/humrep/des144] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
89 Marazuela M, Ramos-leví AM, Borges de Souza P, Zatelli MC. Is receptor profiling useful for predicting pituitary therapy? European Journal of Endocrinology 2018;179:D15-25. [DOI: 10.1530/eje-18-0549] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
90 Maggio R, Fasciani I, Rossi M, Di Gregorio J, Pietrantoni I, Puca V, Flati V, Scarselli M. Variants of G protein-coupled receptors: a reappraisal of their role in receptor regulation. Biochem Soc Trans 2016;44:589-94. [PMID: 27068974 DOI: 10.1042/BST20150239] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
91 Gadelha MR, Wildemberg LE, Bronstein MD, Gatto F, Ferone D. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary 2017;20:100-8. [DOI: 10.1007/s11102-017-0791-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 10.0] [Reference Citation Analysis]
92 Veenstra MJ, de Herder WW, Feelders RA, Hofland LJ. Targeting the somatostatin receptor in pituitary and neuroendocrine tumors. Expert Opinion on Therapeutic Targets 2013;17:1329-43. [DOI: 10.1517/14728222.2013.830711] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
93 Gahete MD, Córdoba-Chacón J, Hergueta-Redondo M, Martínez-Fuentes AJ, Kineman RD, Moreno-Bueno G, Luque RM, Castaño JP. A novel human ghrelin variant (In1-ghrelin) and ghrelin-O-acyltransferase are overexpressed in breast cancer: potential pathophysiological relevance. PLoS One 2011;6:e23302. [PMID: 21829727 DOI: 10.1371/journal.pone.0023302] [Reference Citation Analysis]
94 Zhang Y, Wang M, Ji C, Chen Z, Yang H, Wang L, Yu Y, Qiao N, Ma Z, Ye Z, Shao X, Liu W, Wang Y, Gong W, Melnikov V, Hu L, Lee EJ, Ye H, Wang Y, Li Y, He M, Zhao Y, Zhang Z. Treatment of acromegaly by rosiglitazone via upregulating 15-PGDH in both pituitary adenoma and liver. iScience 2021;24:102983. [PMID: 34485865 DOI: 10.1016/j.isci.2021.102983] [Reference Citation Analysis]
95 Ciganoka D, Balcere I, Kapa I, Peculis R, Valtere A, Nikitina-Zake L, Lase I, Schiöth HB, Pirags V, Klovins J. Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly. Eur J Endocrinol 2011;165:517-25. [PMID: 21810856 DOI: 10.1530/EJE-11-0416] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
96 Gatto F, Arvigo M, Amarù J, Campana C, Cocchiara F, Graziani G, Bruzzone E, Giusti M, Boschetti M, Ferone D. Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells. Pituitary 2019;22:89-99. [PMID: 30483918 DOI: 10.1007/s11102-018-0926-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
97 Fuentes-Fayos AC, Pérez-Gómez JM, G-García ME, Jiménez-Vacas JM, Blanco-Acevedo C, Sánchez-Sánchez R, Solivera J, Breunig JJ, Gahete MD, Castaño JP, Luque RM. SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances. J Exp Clin Cancer Res 2022;41:39. [PMID: 35086552 DOI: 10.1186/s13046-022-02241-4] [Reference Citation Analysis]
98 Gonzalez-Rey E, Pedreño M, Delgado-Maroto V, Souza-Moreira L, Delgado M. Lulling immunity, pain, and stress to sleep with cortistatin. Ann N Y Acad Sci 2015;1351:89-98. [PMID: 25951888 DOI: 10.1111/nyas.12789] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
99 Corica G, Ceraudo M, Campana C, Nista F, Cocchiara F, Boschetti M, Zona G, Criminelli D, Ferone D, Gatto F. Octreotide-Resistant Acromegaly: Challenges and Solutions. Ther Clin Risk Manag 2020;16:379-91. [PMID: 32440136 DOI: 10.2147/TCRM.S183360] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
100 Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 2013;34:228-52. [PMID: 23872332 DOI: 10.1016/j.yfrne.2013.07.005] [Cited by in Crossref: 170] [Cited by in F6Publishing: 152] [Article Influence: 18.9] [Reference Citation Analysis]
101 Durán-Prado M, Gahete MD, Delgado-Niebla E, Martínez-Fuentes AJ, Vázquez-Martínez R, García-Navarro S, Gracia-Navarro F, Malagon MM, Luque RM, Castaño JP. Truncated variants of pig somatostatin receptor subtype 5 (sst5) act as dominant-negative modulators for sst2-mediated signaling. Am J Physiol Endocrinol Metab 2012;303:E1325-34. [PMID: 23032684 DOI: 10.1152/ajpendo.00445.2012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
102 Gadelha MR, Kasuki L, Korbonits M. Novel pathway for somatostatin analogs in patients with acromegaly. Trends in Endocrinology & Metabolism 2013;24:238-46. [DOI: 10.1016/j.tem.2012.11.007] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 9.8] [Reference Citation Analysis]
103 Somvanshi RK, Kumar U. Pathophysiology of GPCR Homo- and Heterodimerization: Special Emphasis on Somatostatin Receptors. Pharmaceuticals (Basel) 2012;5:417-46. [PMID: 24281555 DOI: 10.3390/ph5050417] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
104 Fuentes-Fayos AC, Vázquez-Borrego MC, Jiménez-Vacas JM, Bejarano L, Pedraza-Arévalo S, L-López F, Blanco-Acevedo C, Sánchez-Sánchez R, Reyes O, Ventura S, Solivera J, Breunig JJ, Blasco MA, Gahete MD, Castaño JP, Luque RM. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3. Brain 2020;143:3273-93. [PMID: 33141183 DOI: 10.1093/brain/awaa273] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 8.5] [Reference Citation Analysis]
105 Kasuki L, Wildemberg LE, Gadelha MR. MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly. European Journal of Endocrinology 2018;178:R89-R100. [DOI: 10.1530/eje-17-1006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
106 Puig-Domingo M, Luque RM, Reverter JL, López-Sánchez LM, Gahete MD, Culler MD, Díaz-Soto G, Lomeña F, Squarcia M, Mate JL, Mora M, Fernández-Cruz L, Vidal O, Alastrué A, Balibrea J, Halperin I, Mauricio D, Castaño JP. The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer. PLoS One 2014;9:e85527. [PMID: 24465589 DOI: 10.1371/journal.pone.0085527] [Reference Citation Analysis]
107 Lee M, Lupp A, Mendoza N, Martin N, Beschorner R, Honegger J, Schlegel J, Shively T, Pulz E, Schulz S, Roncaroli F, Pellegata NS. SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary. Endocr Relat Cancer 2015;22:111-9. [PMID: 25515731 DOI: 10.1530/ERC-14-0472] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
108 Herrera-Martínez AD, Gahete MD, Pedraza-Arevalo S, Sánchez-Sánchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Gálvez-Moreno MA, Castaño JP. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Endocrine 2018;59:426-37. [PMID: 29196939 DOI: 10.1007/s12020-017-1482-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
109 Calderon-Aparicio A, Wang BD. Prostate cancer: Alternatively spliced mRNA transcripts in tumor progression and their uses as therapeutic targets. Int J Biochem Cell Biol 2021;141:106096. [PMID: 34653618 DOI: 10.1016/j.biocel.2021.106096] [Reference Citation Analysis]
110 Molè D, Gentilin E, Ibañez-Costa A, Gagliano T, Gahete MD, Tagliati F, Rossi R, Pelizzo MR, Pansini G, Luque RM, Castaño JP, degli Uberti E, Zatelli MC. The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells. Endocrine 2015;50:442-52. [PMID: 25854304 DOI: 10.1007/s12020-015-0594-x] [Reference Citation Analysis]
111 Ibáñez-Costa A, Gahete MD, Rivero-Cortés E, Rincón-Fernández D, Nelson R, Beltrán M, de la Riva A, Japón MA, Venegas-Moreno E, Gálvez MÁ, García-Arnés JA, Soto-Moreno A, Morgan J, Tsomaia N, Culler MD, Dieguez C, Castaño JP, Luque RM. In1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases their aggressive features. Sci Rep 2015;5:8714. [PMID: 25737012 DOI: 10.1038/srep08714] [Reference Citation Analysis]